Targeting BC200/miR218-5p Signaling Axis for Overcoming Temozolomide Resistance and Suppressing Glioma Stemness
<i>Background</i>: Glioblastoma (GB) is one of the most common (~30%) and lethal cancers of the central nervous system. Although new therapies are emerging, chemoresistance to treatment is one of the major challenges in cancer treatment. Brain cytoplasmic 200 (BC200) RNA, also known as B...
Main Authors: | Yu-Kai Su, Jia Wei Lin, Jing-Wen Shih, Hao-Yu Chuang, Iat-Hang Fong, Chi-Tai Yeh, Chien-Min Lin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/9/8/1859 |
Similar Items
-
Temozolomide Chronotherapy in Glioma: A Systematic Review
by: Jason L. Jia, et al.
Published: (2023-02-01) -
Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma
by: Sabrina Fritah, et al.
Published: (2020-09-01) -
Nanomedicine-based combination therapies for overcoming temozolomide resistance in glioblastomas
by: Chun Wang, et al.
Published: (2023-05-01) -
Sitagliptin inhibits the survival, stemness and autophagy of glioma cells, and enhances temozolomide cytotoxicity
by: Fangting You, et al.
Published: (2023-06-01) -
Co-administration of temozolomide (TMZ) and the experimental therapeutic targeting miR-10b, profoundly affects the tumorigenic phenotype of human glioblastoma cells
by: Ming Chen, et al.
Published: (2023-06-01)